Y
Yanning Liu
Researcher at Zhejiang University
Publications - 59
Citations - 2868
Yanning Liu is an academic researcher from Zhejiang University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 19, co-authored 43 publications receiving 1570 citations.
Papers
More filters
Journal ArticleDOI
Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma
TL;DR: The findings suggest that the export of miR-122 via AMSC exosomes represents a novel strategy to enhance HCC chemosensitivity, thereby rendering cancer cells sensitive to chemotherapeutic agents through alteration of mi R-122-target gene expression in HCC cells.
Journal ArticleDOI
Resveratrol Reduces the Proinflammatory Effects and Lipopolysaccharide- Induced Expression of HMGB1 and TLR4 in RAW264.7 Cells
Ying Yang,Shuping Li,Qiao Yang,Yu Shi,Min Zheng,Yanning Liu,Feng Chen,Guangzhong Song,Hangdi Xu,Tian-hong Wan,Jiliang He,Zhi Chen +11 more
TL;DR: Res can block the inflammatory effects induced by LPS in RAW264.7 cells and may also influence TLR4 expression in the HMGB1-TLR4 signaling pathway.
Journal ArticleDOI
Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases.
TL;DR: The biogenesis of M SC exosomes and their physiological functions are reviewed, and the specific biochemical potential of MSC-derived exosome in restoring tissue homeostasis is highlighted.
Journal ArticleDOI
MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway
Guohua Lou,Liang Chen,Caixia Xia,Weina Wang,Jinjin Qi,Aichun Li,Liying Zhao,Zhi Chen,Min Zheng,Yanning Liu +9 more
TL;DR: AMSC-Exo- 199a can be an effective vehicle for miR-199a delivery, and they effectively sensitized HCC to chemotherapeutic agents by targeting mTOR pathway and subsequently inhibiting the m TOR pathway.
Journal ArticleDOI
AMSC-derived exosomes alleviate lipopolysaccharide/d-galactosamine-induced acute liver failure by miR-17-mediated reduction of TXNIP/NLRP3 inflammasome activation in macrophages
TL;DR: Exosome-shuttled miR-17 plays an essential role in AMSC-Exo therapy for ALF by targeting TXNIP and suppressing inflammasome activation in hepatic macrophages and may present as a promising approach for TXnIP/NLRP3 inflammaome-related inflammatory liver diseases.